FDA Fights Back Against ViroPharma's Generic Vancocin Suit

Law360, New York (September 5, 2012, 3:01 PM EDT) -- ViroPharma Inc. doesn't deserve three more years of exclusive rights for its Vancocin, the U.S. Food and Drug Administration told a Washington federal judge Tuesday in a motion to dismiss a lawsuit over the agency's approval of generic versions of the antibiotic.

In its bid to have tossed the suit challenging approval of three generic forms of the gastrointestinal treatment, the FDA said the company hasn’t devised new uses for the medicine warranting continued monopoly protection. The agency downplayed the significance of Vancocin labeling changes it...
To view the full article, register now.